RIM
RCKT icon

RS Investment Management’s Rocket Pharmaceuticals RCKT Stock Holding History

RS Investment Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-396,252
Closed -$18M – 399
2015
Q4 		$18M Buy
396,252
+73,029
+23% +$3.18M 0.16% 194
2015
Q3 		$12.2M Buy
+323,223
New +$14.8M 0.11% 222

Other funds holding RCKT

DPA
Devon Park Associates $30.8M AUM 0.85% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

RS Investment Management's RCKT Position: Q1 2016 in Review

RS Investment Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2016, closing a stake of 396,252 shares — an estimated $18M sold.

RS Investment Management first reported a position in RCKT in Q3 2015 and held it in 2 quarters. The position peaked at $18M in Q4 2015. 58 funds tracked by Wall St. Rank hold RCKT as of Q1 2016.

  • RS Investment Management reported no remaining Rocket Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • RS Investment Management sold 396,252 Rocket Pharmaceuticals shares in Q1 2016, an estimated $18M.
  • RS Investment Management first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • RS Investment Management's Rocket Pharmaceuticals position peaked at $18M in Q4 2015.
  • 58 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2016.

Based on RS Investment Management's 13F filing for Q1 2016, filed 11 May 2016.